patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_182890 | REC_0017101 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 10.3 | 61 | female | 1 | 18 | 6 | 3 | osimertinib 80 mg daily | 10.8 | true | MSI-H | 2026-03-15T05:36:02.019284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744233 | REC_0017102 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 8.8 | 51 | female | 0 | 11 | 8.3 | 4 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:36:02.019622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116976 | REC_0017103 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 18.5 | 57 | male | 0 | 13 | 6.4 | 2 | osimertinib 80 mg daily | 8.3 | true | MSI-H | 2026-03-15T05:36:02.020003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288432 | REC_0017104 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 12.4 | 69 | female | 0 | 10 | 5.1 | 7 | sotorasib 960 mg daily | 8.9 | true | MSS | 2026-03-15T05:36:02.020508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826835 | REC_0017105 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 11.3 | 69 | female | 0 | 7 | 3.1 | 1 | entrectinib 600 mg daily | 22 | false | MSS | 2026-03-15T05:36:02.020921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465400 | REC_0017106 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 15.3 | 87 | female | 1 | 14 | 4 | 5 | alectinib 600 mg BID | 7.3 | false | MSI-H | 2026-03-15T05:36:02.021319+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538958 | REC_0017107 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 7.7 | 74 | female | 1 | 68 | 7.2 | 7 | pembrolizumab 200 mg q3w | 12.9 | true | MSS | 2026-03-15T05:36:02.021709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703097 | REC_0017108 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 9.2 | 60 | male | 1 | 61 | 3.2 | 1 | pembrolizumab 200 mg q3w | 18.1 | true | MSS | 2026-03-15T05:36:02.022083+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498650 | REC_0017109 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 17.2 | 68 | female | 1 | 13 | 6.2 | 7 | pembrolizumab 200 mg q3w | 8.8 | false | MSS | 2026-03-15T05:36:02.022587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925335 | REC_0017110 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 9.6 | 83 | female | 2 | 19 | 6.5 | 2 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:36:02.022939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_999241 | REC_0017111 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 15.9 | 64 | male | 0 | 14 | 4.5 | 3 | osimertinib 80 mg daily | 11.1 | false | MSI-H | 2026-03-15T05:36:02.023248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768932 | REC_0017112 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 19 | 15.3 | 80 | female | 2 | 10 | 5.6 | 0 | osimertinib 80 mg daily | 35.5 | true | MSS | 2026-03-15T05:36:02.023541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222953 | REC_0017113 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 16.7 | 70 | male | 3 | 14 | 7.7 | 1 | entrectinib 600 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:36:02.023862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831140 | REC_0017114 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 10.4 | 68 | male | 0 | 22 | 5.9 | 5 | entrectinib 600 mg daily | 4.9 | true | MSI-H | 2026-03-15T05:36:02.024265+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159334 | REC_0017115 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 11.8 | 90 | female | 3 | 20 | 6.6 | 1 | osimertinib 80 mg daily | 16.6 | true | MSS | 2026-03-15T05:36:02.024611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_775371 | REC_0017116 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 4.1 | 59 | male | 0 | 53 | 5.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:36:02.024922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729231 | REC_0017117 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 5.4 | 57 | male | 1 | 15 | 2.6 | 8 | pembrolizumab 200 mg q3w | 7.7 | false | MSS | 2026-03-15T05:36:02.025247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219394 | REC_0017118 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 3.3 | 68 | female | 1 | 71 | 4.8 | 1 | pembrolizumab 200 mg q3w | 18.6 | false | MSS | 2026-03-15T05:36:02.025567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167699 | REC_0017119 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 14 | 63 | female | 0 | 8 | 5.6 | 6 | sotorasib 960 mg daily | 16.6 | false | MSI-H | 2026-03-15T05:36:02.025921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404419 | REC_0017120 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 14 | 56 | male | 0 | 3 | 5.8 | 2 | osimertinib 80 mg daily | 16.4 | true | MSI-H | 2026-03-15T05:36:02.026297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101630 | REC_0017121 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 18.3 | 59 | male | 1 | 14 | 4.3 | 4 | entrectinib 600 mg daily | 9.1 | true | MSS | 2026-03-15T05:36:02.026662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584697 | REC_0017122 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 7.5 | 81 | female | 2 | 11 | 4.7 | 4 | sotorasib 960 mg daily | 18.5 | false | MSS | 2026-03-15T05:36:02.027201+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124275 | REC_0017123 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 8.9 | 65 | male | 0 | 50 | 6.1 | 3 | carboplatin + paclitaxel + pembrolizumab | 18.4 | false | MSS | 2026-03-15T05:36:02.027596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819073 | REC_0017124 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 10.8 | 70 | female | 2 | 7 | 4.3 | 5 | sotorasib 960 mg daily | 5.5 | false | MSS | 2026-03-15T05:36:02.027971+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610576 | REC_0017125 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 4.4 | 61 | male | 1 | 9 | 5.1 | 1 | osimertinib 80 mg daily | 19.8 | true | MSS | 2026-03-15T05:36:02.028475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183665 | REC_0017126 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 18.9 | 71 | female | 2 | 27 | 3.1 | 4 | entrectinib 600 mg daily | 12.1 | true | MSS | 2026-03-15T05:36:02.028843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823832 | REC_0017127 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 5.9 | 74 | female | 1 | 62 | 7 | 4 | pembrolizumab 200 mg q3w | 7.4 | false | MSS | 2026-03-15T05:36:02.029217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370990 | REC_0017128 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 17 | 9.4 | 63 | female | 1 | 1 | 6.2 | 0 | entrectinib 600 mg daily | 69.2 | false | MSS | 2026-03-15T05:36:02.029591+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590181 | REC_0017129 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 3.6 | 67 | female | 0 | 34 | 6.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:36:02.029989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_301453 | REC_0017130 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12.3 | 76 | female | 2 | 9 | 4.4 | 4 | osimertinib 80 mg daily | 18.8 | false | MSI-H | 2026-03-15T05:36:02.030389+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806498 | REC_0017131 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 6.8 | 56 | male | 1 | 28 | 3.8 | 2 | osimertinib 80 mg daily | 22.5 | false | MSS | 2026-03-15T05:36:02.030777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_818555 | REC_0017132 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 17.2 | 55 | female | 1 | 13 | 3 | 2 | alectinib 600 mg BID | 21.5 | false | MSI-H | 2026-03-15T05:36:02.031169+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685582 | REC_0017133 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 7 | 63 | female | 0 | 27 | 6.2 | 5 | pembrolizumab 200 mg q3w | 9.2 | false | MSS | 2026-03-15T05:36:02.031560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_365190 | REC_0017134 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 16.3 | 58 | female | 1 | 16 | 5.4 | 6 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:02.031933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521393 | REC_0017135 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 18.3 | 63 | female | 1 | 8 | 4.3 | 1 | alectinib 600 mg BID | 22.7 | false | MSI-H | 2026-03-15T05:36:02.032702+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862044 | REC_0017136 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.2 | 81 | male | 3 | 46 | 5.8 | 5 | pembrolizumab 200 mg q3w | 13.3 | false | MSS | 2026-03-15T05:36:02.033184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872671 | REC_0017137 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 12.2 | 65 | female | 0 | 15 | 4 | 1 | entrectinib 600 mg daily | 20.3 | true | MSS | 2026-03-15T05:36:02.033596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257402 | REC_0017138 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 13.8 | 66 | female | 1 | 20 | 5.4 | 2 | entrectinib 600 mg daily | 11.5 | false | MSI-H | 2026-03-15T05:36:02.033969+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529259 | REC_0017139 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 16 | 4.6 | 79 | male | 2 | 13 | 3.3 | 2 | pembrolizumab 200 mg q3w | 22.5 | true | MSS | 2026-03-15T05:36:02.034329+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349566 | REC_0017140 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 14.4 | 67 | female | 1 | 15 | 4.1 | 3 | pembrolizumab 200 mg q3w | 14.1 | true | MSS | 2026-03-15T05:36:02.034674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_531537 | REC_0017141 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.1 | 71 | female | 1 | 56 | 6.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 6.8 | true | MSS | 2026-03-15T05:36:02.035025+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_471216 | REC_0017142 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 15.8 | 71 | male | 1 | 19 | 4 | 5 | entrectinib 600 mg daily | 4 | false | MSI-H | 2026-03-15T05:36:02.035406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229116 | REC_0017143 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 16.7 | 61 | male | 0 | 22 | 4.6 | 2 | sotorasib 960 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:36:02.035797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670054 | REC_0017144 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 36 | 13.1 | 66 | female | 0 | 10 | 3.2 | 4 | alectinib 600 mg BID | 18.2 | true | MSI-H | 2026-03-15T05:36:02.036216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347670 | REC_0017145 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 13.3 | 58 | male | 0 | 16 | 4.6 | 2 | sotorasib 960 mg daily | 16 | false | MSS | 2026-03-15T05:36:02.036951+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721460 | REC_0017146 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 12.7 | 70 | female | 1 | 28 | 2.8 | 6 | osimertinib 80 mg daily | 15.2 | true | MSI-H | 2026-03-15T05:36:02.037674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420475 | REC_0017147 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 9.4 | 83 | female | 2 | 12 | 7.6 | 1 | alectinib 600 mg BID | 12.2 | false | MSS | 2026-03-15T05:36:02.038066+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137789 | REC_0017148 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 19.4 | 61 | male | 1 | 14 | 6.3 | 2 | alectinib 600 mg BID | 16.3 | true | MSS | 2026-03-15T05:36:02.038614+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340890 | REC_0017149 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.6 | 62 | male | 0 | 11 | 4.6 | 6 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:36:02.039143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119011 | REC_0017150 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.1 | 57 | male | 1 | 14 | 5.5 | 7 | pembrolizumab 200 mg q3w | 10.9 | false | MSS | 2026-03-15T05:36:02.039521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527017 | REC_0017151 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 12.6 | 59 | male | 1 | 5 | 6.3 | 3 | alectinib 600 mg BID | 7.4 | false | MSS | 2026-03-15T05:36:02.039915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990762 | REC_0017152 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.4 | 77 | male | 1 | 55 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 6 | true | MSS | 2026-03-15T05:36:02.040509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574673 | REC_0017153 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 9.6 | 66 | female | 1 | 24 | 4.9 | 2 | osimertinib 80 mg daily | 4.5 | true | MSS | 2026-03-15T05:36:02.040963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183711 | REC_0017154 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 9.6 | 74 | female | 1 | 21 | 5.3 | 0 | osimertinib 80 mg daily | 18.2 | false | MSS | 2026-03-15T05:36:02.041525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538614 | REC_0017155 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 8.3 | 58 | male | 1 | 23 | 5.7 | 1 | osimertinib 80 mg daily | 25.1 | false | MSS | 2026-03-15T05:36:02.041933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752633 | REC_0017156 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 9.9 | 79 | female | 1 | 17 | 5.4 | 7 | alectinib 600 mg BID | 6.4 | false | MSS | 2026-03-15T05:36:02.042252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618691 | REC_0017157 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.8 | 67 | female | 1 | 19 | 6.2 | 6 | entrectinib 600 mg daily | 11 | false | MSI-H | 2026-03-15T05:36:02.042575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_156974 | REC_0017158 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 11.3 | 75 | female | 1 | 20 | 4.5 | 2 | sotorasib 960 mg daily | 16 | true | MSI-H | 2026-03-15T05:36:02.043003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633766 | REC_0017159 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.6 | 55 | male | 1 | 20 | 3.2 | 5 | osimertinib 80 mg daily | 8.8 | false | MSI-H | 2026-03-15T05:36:02.043836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305341 | REC_0017160 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 21.6 | 72 | female | 1 | 11 | 7 | 1 | entrectinib 600 mg daily | 26.2 | false | MSS | 2026-03-15T05:36:02.044524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_886505 | REC_0017161 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 13.9 | 65 | female | 1 | 16 | 6.7 | 1 | alectinib 600 mg BID | 19.6 | false | MSS | 2026-03-15T05:36:02.045286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_469818 | REC_0017162 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 6.6 | 73 | female | 2 | 50 | 5.7 | 4 | pembrolizumab 200 mg q3w | 11.2 | true | MSS | 2026-03-15T05:36:02.046085+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_579540 | REC_0017163 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 8.3 | 52 | male | 0 | 16 | 5.8 | 2 | alectinib 600 mg BID | 20.2 | true | MSS | 2026-03-15T05:36:02.046543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_913886 | REC_0017164 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 11 | 53 | male | 0 | 11 | 5.4 | 2 | alectinib 600 mg BID | 17.4 | false | MSI-H | 2026-03-15T05:36:02.046939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153309 | REC_0017165 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 16.9 | 66 | female | 1 | 18 | 7.1 | 6 | osimertinib 80 mg daily | 13.5 | false | MSS | 2026-03-15T05:36:02.047364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_391598 | REC_0017166 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.9 | 66 | male | 1 | 11 | 6 | 7 | osimertinib 80 mg daily | 9.8 | true | MSS | 2026-03-15T05:36:02.052052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363063 | REC_0017167 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 16 | 12.3 | 77 | male | 2 | 18 | 7.4 | 2 | osimertinib 80 mg daily | 19.3 | false | MSI-H | 2026-03-15T05:36:02.054783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643521 | REC_0017168 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 11.6 | 73 | female | 1 | 10 | 6.7 | 5 | osimertinib 80 mg daily | 11.1 | false | MSS | 2026-03-15T05:36:02.055352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507154 | REC_0017169 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 8.2 | 58 | male | 1 | 81 | 4.4 | 6 | pembrolizumab 200 mg q3w | 14.4 | true | MSS | 2026-03-15T05:36:02.056304+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331274 | REC_0017170 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 3.8 | 74 | female | 2 | 26 | 6.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 30.9 | false | MSS | 2026-03-15T05:36:02.056780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507387 | REC_0017171 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 11 | 73 | female | 0 | 12 | 5.3 | 3 | entrectinib 600 mg daily | 10.5 | true | MSI-H | 2026-03-15T05:36:02.057164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554876 | REC_0017172 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 6.5 | 77 | female | 2 | 23 | 6.7 | 4 | pembrolizumab 200 mg q3w | 13.6 | true | MSS | 2026-03-15T05:36:02.057526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110149 | REC_0017173 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 10.4 | 58 | female | 0 | 9 | 6.7 | 6 | osimertinib 80 mg daily | 12 | false | MSI-H | 2026-03-15T05:36:02.057874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645066 | REC_0017174 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 16.4 | 54 | female | 0 | 9 | 4.6 | 6 | entrectinib 600 mg daily | 9.9 | false | MSS | 2026-03-15T05:36:02.058462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916898 | REC_0017175 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 15 | 4.8 | 67 | female | 1 | 34 | 6 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.8 | true | MSS | 2026-03-15T05:36:02.058881+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934394 | REC_0017176 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 13.2 | 65 | male | 1 | 11 | 5.3 | 2 | osimertinib 80 mg daily | 17.3 | true | MSI-H | 2026-03-15T05:36:02.059295+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339406 | REC_0017177 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 17.1 | 60 | female | 1 | 9 | 4.2 | 2 | sotorasib 960 mg daily | 16.7 | false | MSI-H | 2026-03-15T05:36:02.059687+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304559 | REC_0017178 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 18.6 | 72 | female | 0 | 14 | 5.2 | 2 | osimertinib 80 mg daily | 22.8 | false | MSI-H | 2026-03-15T05:36:02.060033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327163 | REC_0017179 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 4.9 | 61 | male | 1 | 46 | 4.1 | 1 | pembrolizumab 200 mg q3w | 18.4 | false | MSS | 2026-03-15T05:36:02.060677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140905 | REC_0017180 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 15.2 | 64 | female | 0 | 16 | 5 | 1 | osimertinib 80 mg daily | 15.2 | false | MSS | 2026-03-15T05:36:02.061062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312876 | REC_0017181 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 9.2 | 63 | male | 1 | 10 | 4.6 | 1 | pembrolizumab 200 mg q3w | 12.9 | false | MSS | 2026-03-15T05:36:02.061395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_746215 | REC_0017182 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 16 | 10 | 77 | female | 1 | 14 | 6 | 2 | osimertinib 80 mg daily | 21.3 | true | MSS | 2026-03-15T05:36:02.061696+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998645 | REC_0017183 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 13 | 8.8 | 76 | female | 2 | 6 | 5.3 | 6 | pembrolizumab 200 mg q3w | 11.2 | false | MSS | 2026-03-15T05:36:02.061989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643641 | REC_0017184 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 6.8 | 74 | female | 1 | 11 | 3.6 | 2 | osimertinib 80 mg daily | 21.6 | false | MSS | 2026-03-15T05:36:02.062295+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653683 | REC_0017185 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 7.7 | 79 | female | 2 | 33 | 6.3 | 1 | pembrolizumab 200 mg q3w | 22.1 | true | MSS | 2026-03-15T05:36:02.062604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127958 | REC_0017186 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 13 | 70 | female | 3 | 18 | 6.8 | 6 | osimertinib 80 mg daily | 11 | false | MSI-H | 2026-03-15T05:36:02.062918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978615 | REC_0017187 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13.9 | 69 | female | 0 | 3 | 5.6 | 7 | osimertinib 80 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:36:02.063411+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167365 | REC_0017188 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 11.4 | 70 | female | 1 | 17 | 4.7 | 7 | osimertinib 80 mg daily | 9 | false | MSI-H | 2026-03-15T05:36:02.063775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703748 | REC_0017189 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 2.9 | 72 | female | 1 | 36 | 5 | 8 | carboplatin + paclitaxel + pembrolizumab | 13.7 | false | MSS | 2026-03-15T05:36:02.064233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486244 | REC_0017190 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 7.8 | 80 | female | 1 | 59 | 4.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 7.3 | false | MSS | 2026-03-15T05:36:02.064654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331312 | REC_0017191 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 14.1 | 51 | female | 0 | 19 | 3.2 | 1 | entrectinib 600 mg daily | 13.2 | true | MSI-H | 2026-03-15T05:36:02.065059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961750 | REC_0017192 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 19.6 | 58 | female | 0 | 13 | 5.2 | 6 | alectinib 600 mg BID | 13.4 | false | MSI-H | 2026-03-15T05:36:02.065422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171606 | REC_0017193 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 9.2 | 71 | male | 2 | 21 | 7.7 | 8 | osimertinib 80 mg daily | 11.6 | true | MSS | 2026-03-15T05:36:02.065736+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413407 | REC_0017194 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 10.7 | 81 | female | 3 | 14 | 7.3 | 8 | osimertinib 80 mg daily | 16.9 | true | MSI-H | 2026-03-15T05:36:02.066071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141117 | REC_0017195 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 5 | 66 | female | 1 | 33 | 6.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 15.8 | false | MSS | 2026-03-15T05:36:02.066415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_815996 | REC_0017196 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 9.1 | 58 | male | 0 | 15 | 5.4 | 2 | osimertinib 80 mg daily | 11.1 | true | MSS | 2026-03-15T05:36:02.066797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617498 | REC_0017197 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 38 | 6.2 | 76 | female | 0 | 64 | 5.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.1 | true | MSS | 2026-03-15T05:36:02.067131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353909 | REC_0017198 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 7.6 | 65 | female | 0 | 10 | 6 | 6 | sotorasib 960 mg daily | 10.5 | false | MSS | 2026-03-15T05:36:02.067461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210958 | REC_0017199 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 29 | 6.4 | 77 | female | 1 | 9 | 6.9 | 1 | pembrolizumab 200 mg q3w | 27.6 | false | MSS | 2026-03-15T05:36:02.067761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_297178 | REC_0017200 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 6.8 | 72 | male | 1 | 11 | 6.4 | 6 | sotorasib 960 mg daily | 16.1 | true | MSS | 2026-03-15T05:36:02.068371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.